Abstract: In various embodiments, a style comparison application compares geometric styles of different three dimensional (3D) computer-aided design (CAD) objects. In operation, the style comparison application executes a trained neural network one or more times to map 3D CAD objects to feature map sets. The style comparison application computes a first set of style signals based on a first feature set included in the feature map sets. The style comparison application computes a second set of style signals based on a second feature set included in the feature map sets. Based on the first set of style signals and the second set of style signals, the style comparison application determines a value for a style comparison metric. The value for the style comparison metric quantifies a similarity or a dissimilarity in geometric style between a first 3D CAD object and a second 3D CAD object.

Abstract: In various embodiments, a style comparison metric application generates a style comparison metric for pairs of different three dimensional (3D) computer-aided design (CAD) objects. In operation, the style comparison metric application executes a trained neural network any number of times to map 3D CAD objects to feature maps. Based on the feature maps, the style comparison metric application computes style signals. The style comparison metric application determines values for weights based on the style signals. The style comparison metric application generates the style comparison metric based on the weights and a parameterized style comparison metric.

Abstract: In various embodiments, a style comparison application generates visualization(s) of geometric style gradient(s). The style comparison application generates a first set of style signals based on a first 3D CAD object and generates a second set of style signals based on a second 3D CAD object. Based on the first and second sets of style signals, the style comparison application computes a different partial derivative of a style comparison metric for each position included in a set of positions associated with the first 3D CAD object to generate a geometric style gradient. The style comparison application generates a graphical element based on at least one of the direction or the magnitude of a vector in the geometric style gradient and positions the graphical element relative to a graphical representation of the first 3D CAD object within a graphical user interface to generate a visualization of the geometric style gradient.

Abstract: In various embodiments, a style comparison metric application generates a style comparison metric for pairs of different three dimensional (3D) computer-aided design (CAD) objects. In operation, the style comparison metric application executes a trained neural network any number of times to map 3D CAD objects to feature maps. Based on the feature maps, the style comparison metric application computes style signals. The style comparison metric application determines values for weights based on the style signals. The style comparison metric application generates the style comparison metric based on the weights and a parameterized style comparison metric.

Abstract: In various embodiments, a style comparison application compares geometric styles of different three dimensional (3D) computer-aided design (CAD) objects. In operation, the style comparison application executes a trained neural network one or more times to map 3D CAD objects to feature map sets. The style comparison application computes a first set of style signals based on a first feature set included in the feature map sets. The style comparison application computes a second set of style signals based on a second feature set included in the feature map sets. Based on the first set of style signals and the second set of style signals, the style comparison application determines a value for a style comparison metric. The value for the style comparison metric quantifies a similarity or a dissimilarity in geometric style between a first 3D CAD object and a second 3D CAD object.

Abstract: Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

Abstract: Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

Abstract: Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Abstract: The present application relates to compounds of Formula I as defined herein, and methods for treating pain and other conditions related to TRPV3.

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.

Abstract: Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.

Abstract: A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.

Abstract: Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking cessation, weight reduction, obsessive-compulsive disorder, various forms of depression, traumatic brain injury, stroke, and narcolepsy.

Abstract: Disclosed are certain cocaine analogs useful for imaging of cocaine receptors and dopamine receptors. Also disclosed are analogs useful for imaging diagnostics for Parkinson's disease.